Sattahipmycin, a Hexacyclic Xanthone Produced by a Marine-Derived Streptomyces

  • J Nat Prod. 2022 May 27;85(5):1211-1217. doi: 10.1021/acs.jnatprod.1c00870.
Kantinan Leetanasaksakul  1  2 ,  Wilaiwan Koomsiri  1  2 ,  Takuya Suga  3 ,  Hirotaka Matsuo  3 ,  Rei Hokari  3 ,  Pakorn Wattana-Amorn  4 ,  Yo Ko Takahashi  3 ,  Kazuro Shiomi  3  5 ,  Takuji Nakashima  3  5 ,  Yuki Inahashi  3 ,  Arinthip Thamchaipenet  1  2
Affiliations
  • 1. Department of Genetics, Faculty of Science, Kasetsart University, Chatuchak, Bangkok 10900, Thailand.
  • 2. Omics Center for Agriculture, Bioresources, Food and Health, Kasetsart University (OmiKU), Bangkok 10900, Thailand.
  • 3. Kitasato Institute for Life Sciences (Present: O̅mura Satoshi Memorial Institute), Kitasato University, Tokyo 108-8641, Japan.
  • 4. Department of Chemistry, Special Research Unit for Advanced Magnetic Resonance and Center of Excellence for Innovation in Chemistry, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand.
  • 5. Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan.
PMID: 35512262 DOI: 10.1021/acs.jnatprod.1c00870
Abstract

Sattahipmycin was isolated from the mycelium of marine-derived Streptomyces sp. GKU 257-1 by following the antibiofilm activity against E. coli NBRC 3972 throughout the purification steps. The structure of sattahipmycin was determined to be a new polycyclic xanthone related to xantholipin but lacking a dioxymethylene and a chlorinated carbon. This compound showed activity toward Gram-positive bacteria and Plasmodium falciparum, antibiofilm formation of Escherichia coli, and cytotoxicity to human Cancer cell lines. Using genome sequence data, a biosynthetic pathway leading to sattahipmycin has been proposed involving an uncharacterized type II polyketide synthase biosynthetic gene cluster.